DE69732170D1 - Formulierung mit verzögerter Freisetzung enthaltend Kollagen und Glykosaminoglykan - Google Patents

Formulierung mit verzögerter Freisetzung enthaltend Kollagen und Glykosaminoglykan

Info

Publication number
DE69732170D1
DE69732170D1 DE69732170T DE69732170T DE69732170D1 DE 69732170 D1 DE69732170 D1 DE 69732170D1 DE 69732170 T DE69732170 T DE 69732170T DE 69732170 T DE69732170 T DE 69732170T DE 69732170 D1 DE69732170 D1 DE 69732170D1
Authority
DE
Germany
Prior art keywords
glycosaminoglycan
release formulation
formulation containing
containing collagen
formulated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69732170T
Other languages
English (en)
Other versions
DE69732170T2 (de
Inventor
Norimasa Koseki
Akihiko Sano
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Koken Co Ltd
Sumitomo Pharma Co Ltd
Original Assignee
Koken Co Ltd
Sumitomo Pharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Koken Co Ltd, Sumitomo Pharmaceuticals Co Ltd filed Critical Koken Co Ltd
Application granted granted Critical
Publication of DE69732170D1 publication Critical patent/DE69732170D1/de
Publication of DE69732170T2 publication Critical patent/DE69732170T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2063—Proteins, e.g. gelatin

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE69732170T 1996-10-09 1997-10-09 Formulierung mit verzögerter Freisetzung enthaltend Kollagen und Glykosaminoglykan Expired - Fee Related DE69732170T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP26880196 1996-10-09
JP26880196 1996-10-09

Publications (2)

Publication Number Publication Date
DE69732170D1 true DE69732170D1 (de) 2005-02-10
DE69732170T2 DE69732170T2 (de) 2005-12-15

Family

ID=17463462

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69732170T Expired - Fee Related DE69732170T2 (de) 1996-10-09 1997-10-09 Formulierung mit verzögerter Freisetzung enthaltend Kollagen und Glykosaminoglykan

Country Status (9)

Country Link
US (1) US5922356A (de)
EP (1) EP0838219B1 (de)
KR (1) KR100577041B1 (de)
AT (1) ATE286384T1 (de)
AU (1) AU727049B2 (de)
CA (1) CA2217134A1 (de)
DE (1) DE69732170T2 (de)
ES (1) ES2236775T3 (de)
NZ (1) NZ328898A (de)

Families Citing this family (319)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW586934B (en) * 1997-05-19 2004-05-11 Sumitomo Pharma Immunopotentiating composition
US7241730B2 (en) 1998-08-27 2007-07-10 Universitat Zurich Enzyme-mediated modification of fibrin for tissue engineering: fibrin formulations with peptides
US7615373B2 (en) * 1999-02-25 2009-11-10 Virginia Commonwealth University Intellectual Property Foundation Electroprocessed collagen and tissue engineering
US20020081732A1 (en) * 2000-10-18 2002-06-27 Bowlin Gary L. Electroprocessing in drug delivery and cell encapsulation
US20040018226A1 (en) * 1999-02-25 2004-01-29 Wnek Gary E. Electroprocessing of materials useful in drug delivery and cell encapsulation
US6083933A (en) * 1999-04-19 2000-07-04 Stellar International Inc. Treatment of cystitis-like symptoms with chondroitin sulfate following administration of a challenge solution
JP2003525916A (ja) * 1999-04-22 2003-09-02 エイドゲントシッシュ テクニーシェ ホッシュール チューリッヒ モディファイドタンパク質マトリクス
EP1178834B1 (de) * 1999-04-22 2006-01-04 Eidgenössische Technische Hochschule (ETH) Kontrollierte abgabe der wachstumsfaktoren von heparin enthaltenden matrizen
CA2457162A1 (en) * 2000-09-01 2002-03-07 Virginia Commonwealth University Intellectual Property Foundation Electroprocessed fibrin-based matrices and tissues
CA2325842C (en) * 2000-11-02 2007-08-07 Lisa Mckerracher Methods for making and delivering rho-antagonist tissue adhesive formulations to the injured mammalian central and peripheral nervous systems and uses thereof
US7182944B2 (en) * 2001-04-25 2007-02-27 The United States Of America As Represented By The Department Of Health And Human Services Methods of increasing distribution of nucleic acids
US7906102B2 (en) 2001-10-03 2011-03-15 Vanderbilt University Ligands to radiation-induced molecules
WO2003041723A1 (de) * 2001-11-12 2003-05-22 Reinmueller Johannes Pharmazeutische anwendungen von hyaluronsäure-präparaten
AU2003244459A1 (en) * 2002-02-04 2003-09-02 Koken Co., Ltd. Preparations for treating bone fracture or bone loss or elevating bone density
JP4632664B2 (ja) 2002-02-13 2011-02-16 デューク ユニバーシティ 非ペプチド結合ストレス応答性ポリペプチドによる免疫応答の調節
EP2301573A1 (de) 2002-10-01 2011-03-30 Novartis Vaccines and Diagnostics, Inc. Zusammensetzungen gegen Krebs und Infektionskrankheiten und Anwendungsverfahren dafür
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US20040161476A1 (en) 2003-02-19 2004-08-19 Hahn Sungtack Samuel Cystitis treatment with high dose chondroitin sulfate
AU2004287875B2 (en) 2003-11-05 2011-06-02 Bausch + Lomb Ireland Limited Modulators of cellular adhesion
FR2862878B1 (fr) * 2003-11-27 2006-03-24 Sofradim Production Substrat metallique revetu d'une composition de collagene et de polysaccharides, procede et applications
GB0402131D0 (en) 2004-01-30 2004-03-03 Isis Innovation Delivery method
US20060039949A1 (en) * 2004-08-20 2006-02-23 Nycz Jeffrey H Acetabular cup with controlled release of an osteoinductive formulation
US20060045902A1 (en) * 2004-09-01 2006-03-02 Serbousek Jon C Polymeric wrap for in vivo delivery of osteoinductive formulations
US20060057184A1 (en) * 2004-09-16 2006-03-16 Nycz Jeffrey H Process to treat avascular necrosis (AVN) with osteoinductive materials
US8137664B2 (en) * 2005-02-02 2012-03-20 Sdgi Holdings, Inc. Method and kit for repairing a defect in bone
US20090156545A1 (en) * 2005-04-01 2009-06-18 Hostetler Karl Y Substituted Phosphate Esters of Nucleoside Phosphonates
WO2006137953A1 (en) 2005-04-01 2006-12-28 The Regents Of The Univerisity Of California Phosphono-pent-2-en-1-yl nucleosides and analogs
CA2985444C (en) 2005-05-17 2019-03-12 Sarcode Bioscience Inc. Compositions and methods for treatment of eye disorders
US20070190127A1 (en) 2005-12-30 2007-08-16 Mingdong Zhou Extended release of neuregulin for improved cardiac function
WO2007103182A2 (en) * 2006-03-01 2007-09-13 Biogen Idec Ma Inc. Compostions and methods for administering gdnf ligand family proteins
AU2007225139A1 (en) * 2006-03-13 2007-09-20 Encysive Pharmaceuticals, Inc. Methods and compositions for treatment of diastolic heart failure
AU2007225207A1 (en) * 2006-03-13 2007-09-20 Encysive Pharmaceuticals, Inc. Formulations of sitaxsentan sodium
EP2383271B1 (de) 2006-03-13 2013-07-10 Kyorin Pharmaceutical Co., Ltd. Aminochinolone als GSK-3-Hemmer
US20080026061A1 (en) * 2006-06-22 2008-01-31 Reichwein John F Crystalline N-(4-chloro-3-methyl-5-isoxazolyl)-2-[2-methyl-4.5-(methylenedioxy)phenylacetyl]-thiophene-3-sulfonamide
PT2066662E (pt) 2006-09-21 2013-02-13 Kyorin Seiyaku Kk Inibidores de serina-hidrolase
US20080103189A1 (en) 2006-10-19 2008-05-01 Auspex Pharmaceuticals, Inc. Preparation and utility of substituted indoles
US20100137421A1 (en) * 2006-11-08 2010-06-03 Emmanuel Theodorakis Small molecule therapeutics, synthesis of analogues and derivatives and methods of use
WO2008079371A1 (en) * 2006-12-22 2008-07-03 Encysive Pharmaceuticals, Inc. Modulators of c3a receptor and methods of use thereof
CA2696053A1 (en) * 2007-02-28 2008-09-04 Conatus Pharmaceuticals, Inc. Methods for the treatment of liver diseases
WO2008106167A1 (en) * 2007-02-28 2008-09-04 Conatus Pharmaceuticals, Inc. Combination therapy comprising matrix metalloproteinase inhibitors and caspase inhibitors for the treatment of liver diseases
TW200846305A (en) 2007-03-15 2008-12-01 Auspex Pharmaceuticals Inc Substituted phenethylamines with serotoninergic and/or norepinephrinergic activity
US7892776B2 (en) 2007-05-04 2011-02-22 The Regents Of The University Of California Screening assay to identify modulators of protein kinase A
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
WO2008151257A2 (en) 2007-06-04 2008-12-11 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
EP2170062A4 (de) * 2007-07-12 2010-12-29 Tragara Pharmaceuticals Inc Verfahren und zusammensetzungen zur behandlung von krebserkrankungen, tumoren und tumorvermittelten erkrankungen
KR101563018B1 (ko) * 2007-09-11 2015-10-23 교린 세이야꾸 가부시키 가이샤 Ｇｓｋ-３ 억제제로서의 시아노아미노퀴놀론 및 테트라졸로아미노퀴놀론
CN102344457B (zh) 2007-09-12 2015-07-22 杏林制药株式会社 作为 gsk-3 抑制剂的螺环状氨基喹诺酮
ES2830024T3 (es) 2007-10-19 2021-06-02 Novartis Ag Composiciones y métodos para el tratamiento del edema macular
WO2009079712A1 (en) 2007-12-24 2009-07-02 The University Of Queensland Coating method
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
CA2749347C (en) 2008-02-07 2018-03-27 The University Of Queensland Patch production
ES2610989T3 (es) 2008-03-17 2017-05-04 Ambit Biosciences Corporation 1-(3-(6,7-dimetoxiquinazolin-4-iloxi)fenil)-3-(5-(1,1,1-trifluoro-2-metilpropano-2-ol)isoxazol-3-il)urea como modulador de quinasas RAF en el tratamiento de enfermedades del cáncer
EP2276508A4 (de) * 2008-04-15 2011-12-28 Sarcode Bioscience Inc Freisetzung von lfa-1-antagonisten gegen das magen-darm-system
WO2009139817A2 (en) 2008-04-15 2009-11-19 Sarcode Corporation Crystalline pharmaceutical and methods of preparation and use thereof
US20090298882A1 (en) * 2008-05-13 2009-12-03 Muller George W Thioxoisoindoline compounds and compositions comprising and methods of using the same
MX2010012514A (es) * 2008-05-20 2011-05-30 Cerenis Therapeutics S A Niacina y un medicamento nsaid para tratamiento combinado.
EP2294415A4 (de) * 2008-05-23 2011-10-05 Univ Queensland Analytnachweis mittels mikronadelpflaster mit analytselektiven reagentien
AU2009256157B2 (en) 2008-06-04 2014-12-18 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
CA2729168A1 (en) 2008-07-02 2010-02-04 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of viral infections
EP2321341B1 (de) 2008-07-16 2017-02-22 Synergy Pharmaceuticals Inc. Zur behandlung von erkrankungen des magen-darm-trakts, entzündlichen erkrankungen, krebs und anderen erkrankungen geeignete agonisten von guanylatcyclase
US20110200525A1 (en) * 2008-10-09 2011-08-18 Patz Jr Edward F Vhh antibody fragments for use in the detection and treatment of cancer
AU2009329806A1 (en) 2008-12-22 2010-07-01 The University Of Queensland Patch production
EP2376524B1 (de) 2008-12-31 2017-03-15 Cypralis Limited Derivate von cyclosporin a
WO2010088450A2 (en) 2009-01-30 2010-08-05 Celladon Corporation Methods for treating diseases associated with the modulation of serca
US8568793B2 (en) 2009-02-11 2013-10-29 Hope Medical Enterprises, Inc. Sodium nitrite-containing pharmaceutical compositions
CN105601619A (zh) 2009-02-27 2016-05-25 埃姆比特生物科学公司 调控jak激酶的喹唑啉衍生物和其使用方法
JP5690286B2 (ja) 2009-03-04 2015-03-25 イデニク プハルマセウティカルス，インコーポレイテッド ホスホチオフェン及びホスホチアゾールｈｃｖポリメラーゼ阻害剤
MX2011009413A (es) 2009-03-11 2011-10-21 Ambit Biosciences Corp Combinacion de una indazolilaminopirrolotriazina y taxano para tratamiento contra cancer.
CA2755120C (en) * 2009-03-11 2017-05-16 Kyorin Pharmaceutical Co., Ltd. 7-cycloalkylaminoquinolones as gsk-3 inhibitors
CN102448958B (zh) 2009-03-27 2015-10-21 维特Dc公司 嘧啶基和1,3,5-三嗪基苯并咪唑磺酰胺和其在癌症治疗中的用途
WO2010110686A1 (en) 2009-03-27 2010-09-30 Pathway Therapeutics Limited Pyrimidinyl and 1,3,5 triazinyl benzimidazoles and their use in cancer therapy
US8399456B2 (en) 2009-04-22 2013-03-19 Axikin Pharmaceuticals, Inc. 2,5-disubstituted arylsulfonamide CCR3 antagonists
PE20150759A1 (es) 2009-04-22 2015-05-15 Axikin Pharmaceuticals Inc Antagonistas ccr3 arilsulfonamida
PE20150925A1 (es) 2009-04-22 2015-06-14 Axikin Pharmaceuticals Inc Antagonistas de ccr3 de arilsulfonamida 2,5-disustituida
WO2011003870A2 (en) 2009-07-06 2011-01-13 Creabilis S.A. Mini-pegylated corticosteroids, compositions including same, and methods of making and using same
EP2451802A1 (de) 2009-07-07 2012-05-16 Pathway Therapeutics, Inc. Pyrimidinyl- und 1,3,5-triazinyl-benzimidazole und ihre verwendung in der krebstherapie
ES2655883T5 (es) 2009-07-08 2022-04-18 Hope Medical Entpr Inc D B A Hope Pharmaceuticals Composiciones farmacéuticas que contienen tiosulfato de sodio
US20110020272A1 (en) 2009-07-24 2011-01-27 Ulrich Schubert Combination therapy for treating hepatitis viral infection
AR077712A1 (es) 2009-08-05 2011-09-14 Idenix Pharmaceuticals Inc Inhibidores de serina proteasa macrociclica
CA2770454A1 (en) 2009-08-19 2011-02-24 Ambit Biosciences Corporation Biaryl compounds and methods of use thereof
US8518405B2 (en) 2009-10-08 2013-08-27 The University Of North Carolina At Charlotte Tumor specific antibodies and uses therefor
WO2011050175A1 (en) 2009-10-21 2011-04-28 Sarcode Corporation Crystalline pharmaceutical and methods of preparation and use thereof
TW201120037A (en) 2009-10-26 2011-06-16 Sunesis Pharmaceuticals Inc Compounds and methods for treatment of cancer
WO2011056764A1 (en) 2009-11-05 2011-05-12 Ambit Biosciences Corp. Isotopically enriched or fluorinated imidazo[2,1-b][1,3]benzothiazoles
WO2011064769A1 (en) 2009-11-24 2011-06-03 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Methods and pharmaceutical compositions for the treatment of hot flashes
US20110301235A1 (en) 2009-12-02 2011-12-08 Alquest Therapeutics, Inc. Organoselenium compounds and uses thereof
WO2011075615A1 (en) 2009-12-18 2011-06-23 Idenix Pharmaceuticals, Inc. 5,5-fused arylene or heteroarylene hepatitis c virus inhibitors
WO2011079313A1 (en) * 2009-12-23 2011-06-30 Map Pharmaceuticals, Inc. Novel ergoline analogs
CN102834409A (zh) 2009-12-30 2012-12-19 西尼克斯公司 环孢菌素类似物
WO2011089166A1 (en) 2010-01-19 2011-07-28 Virologik Gmbh Semicarbazone proteasome inhibitors for treating hiv and hepatitis infection
WO2011094890A1 (en) 2010-02-02 2011-08-11 Argusina Inc. Phenylalanine derivatives and their use as non-peptide glp-1 receptor modulators
US9120815B2 (en) 2010-02-05 2015-09-01 Tragara Pharmaceuticals, Inc. Solid state forms of macrocyclic kinase inhibitors
RU2567753C2 (ru) 2010-02-11 2015-11-10 Селджин Корпорейшн Производные арилметокси изоиндолина и композиции, включающие их, и способы их применения
HUE025699T2 (en) 2010-03-02 2016-04-28 Axikin Pharmaceuticals Inc Isotopically enriched arylsulfonamide derivatives as CCR3 antagonists
WO2011112689A2 (en) 2010-03-11 2011-09-15 Ambit Biosciences Corp. Saltz of an indazolylpyrrolotriazine
AU2011227232B2 (en) 2010-03-17 2015-07-09 Axikin Pharmaceuticals Inc. Arylsulfonamide CCR3 antagonists
WO2011150201A2 (en) 2010-05-27 2011-12-01 Ambit Biosciences Corporation Azolyl amide compounds and methods of use thereof
US9296722B2 (en) 2010-05-27 2016-03-29 Ambit Biosciences Corporation Azolyl urea compounds and methods of use thereof
CA2801001A1 (en) 2010-06-01 2011-12-08 Biotheryx, Inc. Hydroxypyridone derivatives, pharmaceutical compositions thereof, and their therapeutic use for treating proliferative diseases
JP6019015B2 (ja) 2010-06-01 2016-11-02 ビオトヘルイク， インコーポレイテッド ６−シクロヘキシル−１−ヒドロキシ−４−メチル−２（１ｈ）−ピリドンを使用する血液悪性疾患の治療方法
SG186229A1 (en) 2010-06-07 2013-01-30 Novomedix Llc Furanyl compounds and the use thereof
US9943673B2 (en) 2010-07-14 2018-04-17 Vaxxas Pty Limited Patch applying apparatus
EP2595615A1 (de) 2010-07-19 2013-05-29 Summa Health System Vitamin c und chromfreies vitamin k sowie zusammensetzungen daraus zur behandlung von nfkb-induzierten leiden oder erkrankungen
US20140200270A1 (en) 2013-01-11 2014-07-17 Summa Health System Vitamins c and k for treating polycystic diseases
WO2012030944A2 (en) 2010-09-01 2012-03-08 Ambit Biosciences Corporation Quinoline and isoquinoline compounds and methods of use thereof
EP2611812A1 (de) 2010-09-01 2013-07-10 Ambit Biosciences Corporation Thienopyridin- und thienopyrimidinverbindungen sowie verfahren zu ihrer verwendung
WO2012030917A1 (en) 2010-09-01 2012-03-08 Ambit Biosciences Corporation An optically active pyrazolylaminoquinazoline, and pharmaceutical compositions and methods of use thereof
CA2809983A1 (en) 2010-09-01 2012-03-08 Ambit Biosciences Corporation Hydrobromide salts of a pyrazolylaminoquinazoline
WO2012030914A1 (en) 2010-09-01 2012-03-08 Ambit Boisciences Corporation 4-azolylaminoquinazoline derivatives and methods of use thereof
EP2611809A1 (de) 2010-09-01 2013-07-10 Ambit Biosciences Corporation Azolopyridin- und azolopyrimidinverbindungen sowie verfahren zu ihrer verwendung
US20120053176A1 (en) 2010-09-01 2012-03-01 Ambit Biosciences Corp. Adenosine a3 receptor modulating compounds and methods of use thereof
EP2611793A1 (de) 2010-09-01 2013-07-10 Ambit Biosciences Corporation 2-cyclochinazolinderivate und verwendungsverfahren dafür
KR20130102060A (ko) 2010-09-01 2013-09-16 암비트 바이오사이언시즈 코포레이션 퀴나졸린 화합물 및 이의 사용 방법
WO2012030912A1 (en) 2010-09-01 2012-03-08 Ambit Biosciences Corporation 7-cyclylquinazoline derivatives and methods of use thereof
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
WO2012044641A1 (en) 2010-09-29 2012-04-05 Pathway Therapeutics Inc. 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
CN103298786B (zh) 2010-10-11 2016-01-20 埃克希金医药品有限公司 芳基磺酰胺盐ccr3拮抗剂
CN103298474B (zh) 2010-11-10 2016-06-29 无限药品股份有限公司 杂环化合物及其用途
JP2014500275A (ja) 2010-12-06 2014-01-09 フォリカ，インコーポレイテッド 禿頭症を治療するため、および毛髪の成長を促進するための方法
CA2821268C (en) 2010-12-14 2021-06-15 National University Of Singapore Human monoclonal antibody with specificity for dengue virus serotype 1 e protein and uses thereof
WO2012080050A1 (en) 2010-12-14 2012-06-21 F. Hoffmann-La Roche Ag Solid forms of a phenoxybenzenesulfonyl compound
CA2824197C (en) 2011-01-10 2020-02-25 Michael Martin Processes for preparing isoquinolinones and solid forms of isoquinolinones
CA2825152A1 (en) 2011-01-31 2012-08-09 Celgene Corporation Pharmaceutical compositions of cytidine analogs and methods of use thereof
WO2012109398A1 (en) 2011-02-10 2012-08-16 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating hcv infections
US20140148473A1 (en) 2011-03-11 2014-05-29 Celgene Corporation Use of 3-(5-amino-2-methyl-4-oxoquinazolin-3(4h)-yl)piperidine-2,6-dione in treatment of immune-related and inflammatory diseases
EP2691388A1 (de) 2011-03-28 2014-02-05 MEI Pharma, Inc. (kondensierte arylamino- und heterocyclylamino-)pyrimidynyl und 1,3,5-triazinyl-benzimidazole, pharmazeutische zusammensetzungen daraus und ihre verwendung zur behandlung von proliferativen erkrankungen
AU2012236722A1 (en) 2011-03-28 2013-10-17 Mei Pharma, Inc. (alpha-substituted cycloalkylamino and heterocyclylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases
JP6042406B2 (ja) 2011-03-28 2016-12-14 メイ プハルマ，インコーポレーテッド （α−置換アラルキルアミノ及びヘテロアリールアルキルアミノ）ピリミジニル及び１，３，５−トリアジニルベンズイミダゾール、それらを含む医薬組成物、並びに増殖性疾患の治療で使用するためのこれらの化合物
EP2691409B1 (de) 2011-03-31 2018-02-21 Idenix Pharmaceuticals LLC. Verbindungen und zusammensetzungen zur behandlung von virusinfektionen
US20120252721A1 (en) 2011-03-31 2012-10-04 Idenix Pharmaceuticals, Inc. Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor
EP2705013B1 (de) 2011-05-04 2016-03-30 Balance Therapeutics, Inc. Pentylentetrazolderivate
RU2013158449A (ru) 2011-06-23 2015-07-27 Мэп Фармасьютикалс, Инк. Новые фторэрголиновые аналоги
CN103946226A (zh) 2011-07-19 2014-07-23 无限药品股份有限公司 杂环化合物及其应用
JP6027610B2 (ja) 2011-07-19 2016-11-16 インフィニティー ファーマシューティカルズ， インコーポレイテッド 複素環式化合物及びその使用
TW201311663A (zh) 2011-08-29 2013-03-16 Infinity Pharmaceuticals Inc 雜環化合物及其用途
TW201329096A (zh) 2011-09-12 2013-07-16 Idenix Pharmaceuticals Inc 經取代羰氧基甲基磷酸醯胺化合物及用於治療病毒感染之藥學組成物
CN103906759A (zh) 2011-09-12 2014-07-02 埃迪尼克斯医药公司 用于治疗病毒感染的化合物和药物组合物
US9630979B2 (en) 2011-09-29 2017-04-25 Infinity Pharmaceuticals, Inc. Inhibitors of monoacylglycerol lipase and methods of their use
WO2013053022A1 (en) 2011-10-12 2013-04-18 The University Of Queensland Delivery device
TW201331221A (zh) 2011-10-14 2013-08-01 Idenix Pharmaceuticals Inc 嘌呤核苷酸化合物類之經取代的３’，５’－環磷酸酯及用於治療病毒感染之醫藥組成物
TWI650321B (zh) 2011-10-14 2019-02-11 美商安比特生物科學公司 雜環化合物及其使用方法
EP2793580A4 (de) 2011-12-19 2015-05-20 Map Pharmaceuticals Inc Neuartige isoergolinderivate
WO2013095708A1 (en) 2011-12-21 2013-06-27 Map Pharmaceuticals, Inc. Novel neuromodulatory compounds
WO2013130600A1 (en) 2012-02-29 2013-09-06 Ambit Biosciences Corporation Solid forms comprising optically active pyrazolylaminoquinazoline, compositions thereof, and uses therewith
AU2013205240B2 (en) 2012-03-16 2016-02-11 Axikin Pharmaceuticals, Inc. 3,5-diaminopyrazole kinase inhibitors
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2013177188A1 (en) 2012-05-22 2013-11-28 Idenix Pharmaceuticals, Inc. 3',5'-cyclic phosphoramidate prodrugs for hcv infection
WO2013177195A1 (en) 2012-05-22 2013-11-28 Idenix Pharmaceuticals, Inc. 3',5'-cyclic phosphate prodrugs for hcv infection
EA031301B1 (ru) 2012-05-22 2018-12-28 Иденикс Фармасьютикалз Ллс D-аминокислотные химические соединения для лечения заболеваний печени
US9012640B2 (en) 2012-06-22 2015-04-21 Map Pharmaceuticals, Inc. Cabergoline derivatives
BR112015001608B1 (pt) 2012-07-25 2022-08-23 Novartis Ag Métodos para purificação e síntese de um composto inibidor lfa-1, mistura reacional e composições compreendendo o dito composto e composto isolado inibidor lfa-1
WO2014025958A2 (en) 2012-08-09 2014-02-13 Celgene Corporation Treatment of immune-related and inflammatory diseases
CA2878954C (en) 2012-08-09 2020-12-08 Benjamin M. Cohen Salts and solid forms of (s)-3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and compositions comprising and methods of using the same
EP2890370B1 (de) 2012-08-31 2019-10-09 The Regents of the University of California Mittel zur behandlung von adipositas, diabetes und verwandten erkrankungen
US9156799B2 (en) 2012-09-07 2015-10-13 Axikin Pharmaceuticals, Inc. Isotopically enriched arylsulfonamide CCR3 antagonists
WO2014055647A1 (en) 2012-10-03 2014-04-10 Mei Pharma, Inc. (sulfinyl and sulfonyl benzimidazolyl) pyrimidines and triazines, pharmaceutical compositions thereof, and their use for treating proliferative diseases
US10513534B2 (en) 2012-10-08 2019-12-24 Idenix Pharmaceuticals Llc 2′-chloro nucleoside analogs for HCV infection
WO2014063019A1 (en) 2012-10-19 2014-04-24 Idenix Pharmaceuticals, Inc. Dinucleotide compounds for hcv infection
US10723754B2 (en) 2012-10-22 2020-07-28 Idenix Pharmaceuticals Llc 2′,4′-bridged nucleosides for HCV infection
JP6584952B2 (ja) 2012-11-01 2019-10-02 インフィニティー ファーマシューティカルズ， インコーポレイテッド Ｐｉ３キナーゼアイソフォームモジュレーターを用いる癌の治療
EP2916830A2 (de) 2012-11-08 2015-09-16 Summa Health System Kombinationen aus vitamin c, vitamin k und einem polyphenol zur wundheilung
US20140140952A1 (en) 2012-11-14 2014-05-22 Idenix Pharmaceuticals, Inc. D-Alanine Ester of Sp-Nucleoside Analog
WO2014078427A1 (en) 2012-11-14 2014-05-22 Idenix Pharmaceuticals, Inc. D-alanine ester of rp-nucleoside analog
MX370519B (es) 2012-11-30 2019-12-17 Novomedix Llc Sulfonamidas con sustitucion biarilo y su uso.
WO2014099941A1 (en) 2012-12-19 2014-06-26 Idenix Pharmaceuticals, Inc. 4'-fluoro nucleosides for the treatment of hcv
SG11201504931SA (en) 2012-12-21 2015-07-30 Map Pharmaceuticals Inc Novel methysergide derivatives
CA2902348C (en) 2013-02-25 2021-11-30 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
WO2014137930A1 (en) 2013-03-04 2014-09-12 Idenix Pharmaceuticals, Inc. Thiophosphate nucleosides for the treatment of hcv
US9309275B2 (en) 2013-03-04 2016-04-12 Idenix Pharmaceuticals Llc 3′-deoxy nucleosides for the treatment of HCV
EP2970194A1 (de) 2013-03-15 2016-01-20 Infinity Pharmaceuticals, Inc. Salze und feste formen von isochinolinonen und zusammensetzung damit sowie verfahren zur verwendung davon
WO2014151206A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
AU2014235209B2 (en) 2013-03-15 2018-06-14 Bausch Health Ireland Limited Guanylate cyclase receptor agonists combined with other drugs
WO2014165542A1 (en) 2013-04-01 2014-10-09 Idenix Pharmaceuticals, Inc. 2',4'-fluoro nucleosides for the treatment of hcv
DK3003309T3 (da) 2013-05-30 2020-12-14 Infinity Pharmaceuticals Inc Behandling af cancer med PI3-kinase-isoform modulatorer
US10005779B2 (en) 2013-06-05 2018-06-26 Idenix Pharmaceuticals Llc 1′,4′-thio nucleosides for the treatment of HCV
EP3027636B1 (de) 2013-08-01 2022-01-05 Idenix Pharmaceuticals LLC D-amino acid phosphoramidate pronucleotide of halogenierte pyrimidine verbindungen für leber krankheiten
CA2922230A1 (en) 2013-08-30 2015-03-05 Ambit Biosciences Corporation Biaryl acetamide compounds and methods of use thereof
NZ631142A (en) 2013-09-18 2016-03-31 Axikin Pharmaceuticals Inc Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors
US20160229866A1 (en) 2013-09-20 2016-08-11 Idenix Pharmaceuticals Inc. Hepatitis c virus inhibitors
WO2015051336A1 (en) 2013-10-03 2015-04-09 David Wise Compositions and methods for treating pelvic pain and other conditions
CA2925944C (en) 2013-10-04 2023-01-10 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9751888B2 (en) 2013-10-04 2017-09-05 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
MY176976A (en) 2013-10-10 2020-08-28 Bausch Health Ireland Ltd Agonists of guanylate cyclase useful for the treatment of opioid induced dysfunctions
WO2015061204A1 (en) 2013-10-21 2015-04-30 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2015061683A1 (en) 2013-10-25 2015-04-30 Idenix Pharmaceuticals, Inc. D-amino acid phosphoramidate and d-alanine thiophosphoramidate pronucleotides of nucleoside compounds useful for the treatment of hcv
EP3063165A1 (de) 2013-11-01 2016-09-07 Idenix Pharmaceuticals LLC D-alanin-phosphoramidat-pronukleotide von 2'-methyl-2'-fluor-guanosin-nukleosid-verbindungen zur behandlung von hcv
CA2931458A1 (en) 2013-11-27 2015-06-04 Idenix Pharmaceuticals Llc Nucleotides for the treatment of liver cancer
WO2015081297A1 (en) 2013-11-27 2015-06-04 Idenix Pharmaceuticals, Inc. 2'-dichloro and 2'-fluoro-2'-chloro nucleoside analogues for hcv infection
US10683321B2 (en) 2013-12-18 2020-06-16 Idenix Pharmaceuticals Llc 4′-or nucleosides for the treatment of HCV
WO2015183346A2 (en) 2014-01-31 2015-12-03 Washington University Imaging and treatment of pathophysiologic conditions by cerenkov radiation
US20170066779A1 (en) 2014-03-05 2017-03-09 Idenix Pharmaceuticals Llc Solid forms of a flaviviridae virus inhibitor compound and salts thereof
SG10201808053XA (en) 2014-03-19 2018-10-30 Infinity Pharmaceuticals Inc Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
CA2943220C (en) 2014-03-20 2024-01-16 Capella Therapeutics, Inc. Benzimidazole derivatives as erbb tyrosine kinase inhibitors for the treatment of cancer
US10202398B2 (en) 2014-03-20 2019-02-12 Capella Therapeutics, Inc. Benzimidazole derivatives as ERBB tyrosine kinase inhibitors for the treatment of cancer
AU2015243437B2 (en) 2014-04-09 2019-08-29 Siteone Therapeutics, Inc. 10',11'-modified saxitoxins useful for the treatment of pain
EP3131914B1 (de) 2014-04-16 2023-05-10 Idenix Pharmaceuticals LLC 3'-substituierte methyl- oder alkynylnukleoside zur behandlung von hcv
WO2015168079A1 (en) 2014-04-29 2015-11-05 Infinity Pharmaceuticals, Inc. Pyrimidine or pyridine derivatives useful as pi3k inhibitors
MX2016014731A (es) 2014-05-12 2017-05-04 Conatus Pharmaceuticals Inc Tratamiento de las complicaciones de la enfermedad cronica del higado con enfermedades de caspasa.
KR20170005492A (ko) 2014-05-28 2017-01-13 아이데닉스 파마슈티칼스 엘엘씨 암의 치료를 위한 뉴클레오시드 유도체
US9974870B2 (en) 2014-06-09 2018-05-22 Washington University Compositions and methods for treatment and imaging using nanoparticles
WO2015195474A1 (en) 2014-06-18 2015-12-23 Biotheryx, Inc. Hydroxypyridone derivatives, pharmaceutical compositions thereof, and their therapeutic use for treating inflammatory, neurodegenerative, or immune-mediated diseases
CN110526912B (zh) 2014-06-19 2023-02-14 武田药品工业株式会社 用于激酶抑制的杂芳基化合物
US9499514B2 (en) 2014-07-11 2016-11-22 Celgene Corporation Antiproliferative compounds and methods of use thereof
AU2015292498B2 (en) 2014-07-23 2020-11-05 Ohio State Innovation Foundation Methods and compositions related to antibody fragments that bind to tumor-associated glycoprotein 72 (TAG-72)
US10449261B2 (en) 2014-07-24 2019-10-22 Washington University Compositions targeting radiation-induced molecules and methods of use thereof
AU2015314830B2 (en) 2014-09-12 2021-01-07 Tobira Therapeutics, Inc. Cenicriviroc combination therapy for the treatment of fibrosis
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP3209647B1 (de) 2014-10-21 2020-06-03 ARIAD Pharmaceuticals, Inc. Kristalline formen von 5-chloro-n4-[2-(dimetnhylphosphoryl)phenyl]-n2-(2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-a-yl]pyrimidin-2,4-diamin
US20170354639A1 (en) 2014-10-24 2017-12-14 Biogen Ma Inc. Diterpenoid derivatives and methods of use thereof
NZ733950A (en) 2014-12-23 2018-08-31 Axikin Pharmaceuticals Inc 3,5-diaminopyrazole kinase inhibitors
BR112017015510A2 (pt) 2015-01-20 2018-01-30 Xoc Pharmaceuticals Inc composto de fórmula estrutural (i), método de tratamento e/ou prevenção, método de agonização do receptor d2 em um indivíduo, método de antagonização do receptor d3 em um indivíduo, método de agonização do receptor 5-ht1d em um indivíduo, método de agonização do receptor 5-ht1a em um indivíduo, método de agonização seletiva do receptor 5-ht1d em vez do receptor 5-ht1b em um indivíduo, método de agonização seletiva do re-ceptor 5-ht2c em vez do receptor 5-ht2a ou 5-ht2b em um indivíduo, método de agonização do receptor 5-ht2c em um indivíduo, método de fornecimento de atividade antagonista funcional no receptor 5-ht2b ou receptor 5-ht7, e, método de fornecimento de atividade antagonista funcional nos receptores adrenérgicos em um indivíduo
JP6856532B2 (ja) 2015-01-20 2021-04-07 エックスオーシー ファーマシューティカルズ インコーポレイテッドＸｏｃ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ エルゴリン化合物およびその使用
AU2016214968B2 (en) 2015-02-02 2021-02-25 Vaxxas Pty Limited Microprojection array applicator and method
EP3303361A1 (de) 2015-05-27 2018-04-11 Idenix Pharmaceuticals LLC Nukleotide zur behandlung von krebs
CN113713108A (zh) 2015-06-23 2021-11-30 纽罗克里生物科学有限公司 用于治疗神经学疾病或病症的vmat2抑制剂
LT3640345T (lt) 2015-08-17 2022-01-10 Kura Oncology, Inc. Vėžiu sergančių pacientų gydymo būdai farneziltransferazės inhibitoriais
US11103259B2 (en) 2015-09-18 2021-08-31 Vaxxas Pty Limited Microprojection arrays with microprojections having large surface area profiles
ES2895155T3 (es) 2015-09-30 2022-02-17 Siteone Therapeutics Inc Saxitoxinas modificadas en 11,13 para el tratamiento del dolor
CA3002074A1 (en) 2015-10-30 2017-05-04 Neurocrine Biosciences, Inc. Valbenazine salts and polymorphs thereof
WO2017079566A1 (en) 2015-11-05 2017-05-11 Conatus Pharmaceuticals, Inc. Caspase inhibitors for use in the treatment of liver cancer
US10112924B2 (en) 2015-12-02 2018-10-30 Astraea Therapeutics, Inc. Piperdinyl nociceptin receptor compounds
JP6869988B2 (ja) 2015-12-23 2021-05-12 ニューロクライン バイオサイエンシーズ，インコーポレイテッド （Ｓ）−（２Ｒ，３Ｒ，１１ｂＲ）−３−イソブチル−９，１０−ジメトキシ−２，３，４，６，７，１１ｂ−ヘキサヒドロ−１Ｈ−ピリド［２，１−ａ］イソキノリン−２−イル２−アミノ−３−メチルブタノエートジ（４−メチルベンゼンスルホネート）の調製のための合成方法
EP3397251A1 (de) 2015-12-31 2018-11-07 Conatus Pharmaceuticals, Inc. Verfahren zur verwendung von caspase-hemmern bei der behandlung von lebererkrankungen
AR107321A1 (es) 2016-01-08 2018-04-18 Celgene Corp Compuestos antiproliferativos, y sus composiciones farmacéuticas y usos
IL296659A (en) 2016-01-08 2022-11-01 Celgene Corp Cancer treatment methods and the use of biomarkers to predict clinical sensitivity to treatments
US10189808B2 (en) 2016-01-08 2019-01-29 Celgene Corporation Solid forms of 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide, and their pharmaceutical compositions and uses
WO2017123634A1 (en) 2016-01-11 2017-07-20 Synergy Pharmaceuticals, Inc. Formulations and methods for treating ulcerative colitis
US10759806B2 (en) 2016-03-17 2020-09-01 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors
AU2017250086A1 (en) 2016-04-11 2018-09-20 Clexio Biosciences Ltd. Deuterated ketamine derivatives
US10047077B2 (en) 2016-04-13 2018-08-14 Skyline Antiinfectives, Inc. Deuterated O-sulfated beta-lactam hydroxamic acids and deuterated N-sulfated beta-lactams
US20190119758A1 (en) 2016-04-22 2019-04-25 Kura Oncology, Inc. Methods of selecting cancer patients for treatment with farnesyltransferase inhibitors
CA3022395A1 (en) 2016-04-29 2017-11-02 Fgh Biotech, Inc. Di-substituted pyrazole compounds for the treatment of diseases
TWI753910B (zh) 2016-05-16 2022-02-01 美商拜歐斯瑞克斯公司 吡啶硫酮、其醫藥組合物及其治療增生性、炎性、神經退化性或免疫介導疾病之治療用途
WO2017214269A1 (en) 2016-06-08 2017-12-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
JP7071981B2 (ja) 2016-09-07 2022-05-19 エフジーエイチ バイオテック，インコーポレーテッド 疾患の治療のための二置換ピラゾール化合物
KR20190058550A (ko) 2016-09-19 2019-05-29 메이 파마, 아이엔씨. 병용 요법
JP2019534290A (ja) 2016-11-03 2019-11-28 クラ オンコロジー， インコーポレイテッド 癌の治療方法において使用するためのファルネシルトランスフェラーゼ阻害剤
TW201828932A (zh) 2016-11-09 2018-08-16 美商諾沃麥迪斯有限責任公司 1,1-二甲基雙胍之亞硝酸鹽、醫藥組合物及使用方法
WO2018089692A1 (en) 2016-11-09 2018-05-17 Phloronol, Inc. Eckol derivatives, methods of synthesis and uses thereof
CN110191705A (zh) 2016-12-01 2019-08-30 亚尼塔公司 治疗癌症的方法
TW202345829A (zh) 2016-12-02 2023-12-01 美商紐羅克里生物科學有限公司 戊苯那嗪（valbenazine）於治療精神分裂症或情感性精神分裂症之用途
CN110769826A (zh) 2017-01-27 2020-02-07 纽罗克里生物科学有限公司 施用某些vmat2抑制剂的方法
MX2019009821A (es) 2017-02-21 2019-12-02 Kura Oncology Inc Metodos para tratar cancer con inhibidores de farnesiltransferasa.
US10137121B2 (en) 2017-02-21 2018-11-27 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
WO2018164996A1 (en) 2017-03-06 2018-09-13 Neurocrine Biosciences, Inc. Dosing regimen for valbenazine
WO2018175324A1 (en) 2017-03-20 2018-09-27 The Broad Institute, Inc. Compounds and methods for regulating insulin secretion
WO2018183781A1 (en) 2017-03-29 2018-10-04 Siteone Therapeutics, Inc. 11,13-modified saxitoxins for the treatment of pain
WO2018183782A1 (en) 2017-03-29 2018-10-04 Siteone Therapeutics, Inc. 11,13-modified saxitoxins for the treatment of pain
JP7152787B2 (ja) 2017-03-31 2022-10-13 ヴァクザス ピーティーワイ リミテッド 表面をコーティングするための装置および方法
US20200179352A1 (en) 2017-04-26 2020-06-11 Neurocrine Biosciences, Inc. Use of valbenazine for treating levodopa-induced dyskinesia
JOP20190219A1 (ar) 2017-05-09 2019-09-22 Cardix Therapeutics LLC تركيبات صيدلانية وطرق لعلاج أمراض القلب والأوعية الدموية
US10085999B1 (en) 2017-05-10 2018-10-02 Arixa Pharmaceuticals, Inc. Beta-lactamase inhibitors and uses thereof
AU2018270295B2 (en) 2017-05-19 2022-03-03 Nflection Therapeutics, Inc. Pyrrolopyridine-aniline compounds for treatment of dermal disorders
KR102659322B1 (ko) 2017-05-19 2024-04-22 엔플렉션 테라퓨틱스, 인코포레이티드 피부병 치료를 위한 융합된 헤테로방향족-아닐린 화합물
CN111132980A (zh) 2017-06-01 2020-05-08 Xoc制药股份有限公司 用于医学的麦角灵衍生物
CA3065371A1 (en) 2017-06-13 2018-12-20 Vaxxas Pty Limited Quality control of substrate coatings
EP3661587A4 (de) 2017-08-04 2021-06-09 Vaxxas Pty Limited Kompakter hoher mechanischer energiespeicher und aktuator mit geringer auslösekraft für die abgabe von mikroprojektions-array-patches (map)
US10806730B2 (en) 2017-08-07 2020-10-20 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
EP3664804A4 (de) 2017-08-07 2021-04-14 Kura Oncology, Inc. Verfahren zur behandlung von krebs mit farnesyltransferase-inhibitoren
EP3684333A2 (de) 2017-09-21 2020-07-29 Neurocrine Biosciences, Inc. Hochdosierte valbenazinformulierung und zusammensetzungen, verfahren und kits dazu
US10993941B2 (en) 2017-10-10 2021-05-04 Neurocrine Biosciences, Inc. Methods for the administration of certain VMAT2 inhibitors
AU2017435893B2 (en) 2017-10-10 2023-06-29 Neurocrine Biosciences, Inc Methods for the administration of certain VMAT2 inhibitors
WO2019113269A1 (en) 2017-12-08 2019-06-13 Kura Oncology, Inc. Methods of treating cancer patients with farnesyltransferase inhibitors
US20210052529A1 (en) 2018-01-10 2021-02-25 Cura Therapeutics, Llc Pharmaceutical compositions comprising dicarboxylic acids and their therapeutic applications
TWI823890B (zh) 2018-01-10 2023-12-01 美商克拉治療有限責任公司 包含苯基磺醯胺之醫藥組合物及其治療應用
EP3806856A1 (de) 2018-06-14 2021-04-21 Neurocrine Biosciences, Inc. Vmat2-inhibitorverbindungen, zusammensetzungen und verfahren im zusammenhang damit
CA3105352A1 (en) 2018-06-29 2020-01-02 Histogen, Inc. (s)-3-(2-(4-(benzyl)-3-oxopiperazin-1-yl)acetamido)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid derivatives and related compounds as caspase inhibitors for treating cardiovascular diseases
BR112021000019A2 (pt) 2018-08-15 2021-04-06 Neurocrine Biosciences Inc. Métodos para administração de certos inibidores de vmat2
US20220009938A1 (en) 2018-10-03 2022-01-13 Siteone Therapeutics, Inc. 11,13-modified saxitoxins for the treatment of pain
CN113286591A (zh) 2018-11-01 2021-08-20 库拉肿瘤学公司 用法尼基转移酶抑制剂治疗癌症的方法
WO2020106308A1 (en) 2018-11-20 2020-05-28 Nflection Therapeutics, Inc. Naphthyridinone-aniline compounds for treatment of dermal disorders
CN113645964A (zh) 2018-11-20 2021-11-12 恩福莱克逊治疗有限公司 用于胎记治疗的芳基苯胺和杂芳基苯胺化合物
WO2020106306A1 (en) 2018-11-20 2020-05-28 Nflection Therapeutics, Inc. Cyanoaryl-aniline compounds for treatment of dermal disorders
JP2022513089A (ja) 2018-11-20 2022-02-07 エヌフレクション セラピューティクス インコーポレイテッド 皮膚癌の処置のためのアリールアニリンおよびヘテロアリールアニリン化合物
JP7407461B2 (ja) 2018-12-19 2024-01-04 シャイ・セラピューティクス・エルエルシー がん、炎症性疾患、ｒａｓ病、及び線維性疾患の処置のためのｒａｓスーパーファミリーと相互作用する化合物
AU2019403379A1 (en) 2018-12-21 2021-07-15 Kura Oncology, Inc. Therapies for squamous cell carcinomas
WO2020132700A1 (en) 2018-12-21 2020-06-25 Fgh Biotech Inc. Methods of using inhibitors of srebp in combination with niclosamide and analogs thereof
EP3921038A1 (de) 2019-02-06 2021-12-15 Dice Alpha, Inc. Il-17a modulators and uses thereof
US20220142983A1 (en) 2019-03-01 2022-05-12 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
MX2021010603A (es) 2019-03-07 2022-01-31 Conatus Pharmaceuticals Inc Inhibidores de caspasa y metodos de uso de los mismos.
US20220143006A1 (en) 2019-03-15 2022-05-12 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
TW202043487A (zh) 2019-03-29 2020-12-01 美商庫拉腫瘤技術股份有限公司 以法尼基轉移酶(farnesyltransferase)抑制劑治療鱗狀細胞癌之方法
US20220168296A1 (en) 2019-04-01 2022-06-02 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
WO2020223583A1 (en) 2019-05-02 2020-11-05 Kura Oncology, Inc. Methods of treating acute myeloid leukemia with farnesyltransferase inhibitors
CA3146157A1 (en) 2019-07-11 2021-01-14 Cura Therapeutics, Llc Sulfone compounds and pharmaceutical compositions thereof, and their therapeutic applications for the treatment of neurodegenerative diseases
WO2021007474A1 (en) 2019-07-11 2021-01-14 Cura Therapeutics, Llc Phenyl compounds and pharmaceutical compositions thereof, and their therapeutic applications
CN114126593A (zh) 2019-07-26 2022-03-01 埃斯佩尔维塔治疗股份有限公司 可用于预防或治疗疾病的官能化的长链烃一元和二元羧酸
US11788091B2 (en) 2019-08-21 2023-10-17 University Of Virginia Patent Foundation Methods and compositions for diagnosing and treating prostate cancer based on long noncoding RNA overlapping the LCK gene that regulates prostate cancer cell growth
US10940141B1 (en) 2019-08-23 2021-03-09 Neurocrine Biosciences, Inc. Methods for the administration of certain VMAT2 inhibitors
KR20220101075A (ko) 2019-09-16 2022-07-19 다이스 알파, 인크. Il-17a 조절인자 및 이의 용도
WO2021059023A1 (en) 2019-09-26 2021-04-01 Abionyx Pharma Sa Compounds useful for treating liver diseases
JP2022551583A (ja) 2019-10-01 2022-12-12 モレキュラー スキン セラピューティクス，インコーポレイティド Ｋｌｋ５／７デュアル阻害剤としてのベンゾキサジノン化合物
CA3179635A1 (en) 2020-05-29 2021-12-02 Boulder Bioscience Llc Methods for improved endovascular thrombectomy using 3,3'-diindolylmethane
WO2021257828A1 (en) 2020-06-18 2021-12-23 Shy Therapeutics, Llc Substituted thienopyrimidines that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
JP2023537632A (ja) 2020-08-14 2023-09-04 サイトワン セラピューティクス インコーポレイテッド 疼痛の処置のためのＮａＶ１．７の非水和ケトン阻害剤
EP4284377A1 (de) 2021-01-27 2023-12-06 Shy Therapeutics LLC Verfahren zur behandlung von fibrotischen erkrankungen
WO2022165000A1 (en) 2021-01-27 2022-08-04 Shy Therapeutics, Llc Methods for the treatment of fibrotic disease
WO2022189856A1 (en) 2021-03-08 2022-09-15 Abionyx Pharma Sa Compounds useful for treating liver diseases
KR20230169979A (ko) 2021-03-10 2023-12-18 다이스 몰레큘스 에스브이, 인크. 알파 v 베타 6 및 알파 v 베타 1 인테그린 억제제 및 그의 용도
WO2022226166A1 (en) 2021-04-22 2022-10-27 Protego Biopharma, Inc. Spirocyclic imidazolidinones and imidazolidinediones for treatment of light chain amyloidosis
EP4347568A1 (de) 2021-05-27 2024-04-10 Protego Biopharma, Inc. Heteroaryldiamid-ire1/xbp1s-aktivatoren
TW202327590A (zh) 2021-11-30 2023-07-16 美商庫拉腫瘤技術股份有限公司 大環化合物及組合物以及其製備及使用方法
WO2023129577A1 (en) 2022-01-03 2023-07-06 Lilac Therapeutics, Inc. Cyclic thiol prodrugs
US11981694B2 (en) 2022-01-03 2024-05-14 Lilac Therapeutics, Inc. Acyclic thiol prodrugs
TW202400593A (zh) 2022-03-28 2024-01-01 美商艾索司特瑞克斯公司 Ｍｙｓｔ家族離胺酸乙醯轉移酶之抑制劑
WO2023192904A1 (en) 2022-03-30 2023-10-05 Biomarin Pharmaceutical Inc. Dystrophin exon skipping oligonucleotides
GB2619907A (en) 2022-04-01 2023-12-27 Kanna Health Ltd Novel crystalline salt forms of mesembrine
TW202406901A (zh) 2022-04-14 2024-02-16 美商必治妥美雅史谷比公司 新穎gspt1化合物以及新穎化合物之使用方法
WO2023201348A1 (en) 2022-04-15 2023-10-19 Celgene Corporation Methods for predicting responsiveness of lymphoma to drug and methods for treating lymphoma
WO2023211990A1 (en) 2022-04-25 2023-11-02 Siteone Therapeutics, Inc. Bicyclic heterocyclic amide inhibitors of na v1.8 for the treatment of pain
TW202406557A (zh) 2022-05-05 2024-02-16 美商拜奧馬林製藥公司 治療杜興氏肌肉失養症之方法
WO2024054832A1 (en) 2022-09-09 2024-03-14 Innovo Therapeutics, Inc. CK1α AND DUAL CK1α / GSPT1 DEGRADING COMPOUNDS
WO2024073473A1 (en) 2022-09-30 2024-04-04 Boulder Bioscience Llc Compositions comprising 3,3'-diindolylmethane for treating non-hemorrhagic closed head injury
WO2024086246A2 (en) 2022-10-18 2024-04-25 Eluciderm Inc. 2-substituted 3,4 a, 5, 7, 8, 8 a-hexahydro-4h-thiop yrano [4,3- djpyrimidin-4-ones for wound treatment
US20240174673A1 (en) 2022-10-26 2024-05-30 Protego Biopharma, Inc. Spirocycle Containing Pyridine Compounds
WO2024092037A1 (en) 2022-10-26 2024-05-02 Protego Biopharma, Inc. Spirocycle containing pyridone compounds
US20240174695A1 (en) 2022-10-26 2024-05-30 Protego Biopharma, Inc. Spirocycle Containing Bicyclic Heteroaryl Compounds
WO2024118801A1 (en) 2022-11-30 2024-06-06 Protego Biopharma, Inc. Linear heteroaryl diamide ire1/xbp1s activators
WO2024118810A1 (en) 2022-11-30 2024-06-06 Protego Biopharma, Inc. Cyclic pyrazole diamide ire1/xbp1s activators

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3484951D1 (de) * 1983-10-14 1991-09-26 Sumitomo Pharma Verlaengerte praeparate mit verzoegerter abgabe.
US5385738A (en) * 1983-10-14 1995-01-31 Sumitomo Pharmaceuticals Company, Ltd. Sustained-release injection
US4774091A (en) * 1983-10-14 1988-09-27 Sumitomo Pharmaceuticals Company, Ltd. Long-term sustained-release preparation
JPS6097918A (ja) * 1983-11-01 1985-05-31 Sumitomo Chem Co Ltd インタ−フエロン持続性製剤
JPH0657658B2 (ja) * 1985-04-11 1994-08-03 住友製薬株式会社 徐放性製剤
JPS6084213A (ja) * 1983-10-14 1985-05-13 Sumitomo Chem Co Ltd 徐放性消炎鎮痛製剤
JPS6089418A (ja) * 1983-10-20 1985-05-20 Sumitomo Chem Co Ltd 徐放性制癌剤
JPS60112713A (ja) * 1983-11-21 1985-06-19 Sumitomo Chem Co Ltd 有用な徐放性注射剤
US4855134A (en) * 1983-10-14 1989-08-08 Sumitomo Pharmaceuticals Company, Limited Sustained-release preparation
JPS60126217A (ja) * 1983-12-14 1985-07-05 Sumitomo Chem Co Ltd 長期徐放性製剤
JPS62186298A (ja) * 1986-02-12 1987-08-14 ヤマハ株式会社 電子楽器の自動伴奏装置
JPH0725688B2 (ja) * 1986-03-31 1995-03-22 住友製薬株式会社 Ｃｓｆ徐放性製剤
JPH021287A (ja) * 1986-12-25 1990-01-05 Terumo Corp 生体適合性材料、これを用いた医用材料およびマイクロカプセルならびにそれらの製法
ATE90570T1 (de) * 1988-01-29 1993-07-15 Sumitomo Pharma Verbesserte formulierungen mit kontrollierter abgabe.
JP2641755B2 (ja) * 1988-01-29 1997-08-20 住友製薬株式会社 コントロールリリース製剤
ES2058827T3 (es) * 1989-01-31 1994-11-01 Coletica Uso de soluciones de atelocolageno y poliholosidos, por ejemplo glicosaminoglicanos, para la fabricacion de microcapsulas, a microcapsulas preparadas de esta manera, a procedimientos para la fabricacion de estas microcapsulas y a composiciones cosmeticas, farmaceuticas o alimenti
EP0499119B1 (de) * 1991-02-14 1995-05-10 Peter J. Balsells Schwingungsdämpfende Lagervorrichtung
EP0503583A1 (de) * 1991-03-12 1992-09-16 Takeda Chemical Industries, Ltd. Erythropoietin enthaltendes Arzneimittel mit verzögerter Wirkstofffreigabe
US5344644A (en) * 1991-08-01 1994-09-06 Takeda Chemical Industries, Ltd. Water-soluble composition for sustained-release
CA2140053C (en) * 1994-02-09 2000-04-04 Joel S. Rosenblatt Collagen-based injectable drug delivery system and its use
US5693341A (en) * 1995-03-16 1997-12-02 Collagen Corporation Affinity bound collagen matrices for the delivery of biologically active agents

Also Published As

Publication number Publication date
ATE286384T1 (de) 2005-01-15
CA2217134A1 (en) 1998-04-09
KR19980032708A (ko) 1998-07-25
KR100577041B1 (ko) 2006-12-04
EP0838219A1 (de) 1998-04-29
EP0838219B1 (de) 2005-01-05
DE69732170T2 (de) 2005-12-15
NZ328898A (en) 1999-02-25
US5922356A (en) 1999-07-13
AU727049B2 (en) 2000-11-30
ES2236775T3 (es) 2005-07-16
AU3990797A (en) 1998-04-23

Similar Documents

Publication Publication Date Title
DE69732170D1 (de) Formulierung mit verzögerter Freisetzung enthaltend Kollagen und Glykosaminoglykan
CR9879A (es) Moduladores de ccr5 (divisional de la solicitud n° 6392)
DE69530926D1 (de) Mittel zur förderung des haarwachstums
DE69736441D1 (de) Pharmazeutische zusammensetzung zur behandlung von neurologischen und neuropsychiatrischen erkrankungen
ES2099977T3 (es) Composiciones de liberacion prolongada para tratar enfermedades periodontales.
ATE452640T1 (de) Mittel für erkrankungen assoziert mit knochensubstanzverlust
ATE232862T1 (de) Oxazolidinon derivate und diese enthaltende pharmazeutische zusammensetzungen
NL980008I1 (nl) Gebruik van sertindool voor de behandeling van schizofrenie.
HUP0102482A2 (hu) Készítmények az emberi tetű elpusztítására
FI951856A0 (fi) Farmaseuttinen koostumus osteoporoosin hoitamiseksi
BR9708114A (pt) Análogos xantona para o tratamento de doenças infecciosas.
DE69930271T8 (de) Medizinische zusammensetzungen zur behandlung von augenerkrankungen
DE60022683D1 (de) Nervenschutzmittel
DE69834500D1 (de) Xanthinderivative zur behandlung von hirnischämie
ES2160643T3 (es) Composiciones que contienen g-csf y proteina de union al tnf.
EA199800717A1 (ru) Способ лечения заболеваний млекопитающих и цвиттерионная композиция
DE69917074D1 (de) Optisch aktives pyridyl-4h-1,2,4-oxadiazinderivat und seine verwendung zur behandlung von gefässkrankheiten
AR005970A1 (es) Compuestos de benzotiofeno y formulaciones farmaceuticas que los contienen como agente activo
HUP0000110A2 (hu) Azaciklusos, azabiciklusos vagy tetrahidropiridinszármazékokat tartalmazó, fájdalom kezelésére alkalmas gyógyászati készítmények
ATE216891T1 (de) Verwendung von immunosuppressiva zur behandlung der schizophrenie
PT972521E (pt) Composicao farmaceutica contendo estimuladores de interferao gama
EP0826374A3 (de) Pharmazeutische Zusammensetzung zur Verhütung und/oder Behandlung von Krankheiten mit Bezug auf Apoptose
LT96094A (en) The active ingredient of pharmaceutical composition for treating constipation
ATE333287T1 (de) Prophylaxe und behandlung von autoimmunen entmyelinisierungserkrankungen durch fas- antagonisten
UA30143C2 (uk) Лікувальний препарат для профілактики та лікування інфекційних та запальних захворювань

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: DAINIPPON SUMITOMO PHARMA CO., LTD., OSAKA, JP

Owner name: KOKEN CO., LTD., TOKIO/TOKYO, JP

8339 Ceased/non-payment of the annual fee